Rallybio has become the latest company to hitch its antibody drug development efforts to AbCellera. The partners will co-develop up to five rare disease therapeutic targets in a risk-sharing pact, starting with a metabolic disease program.
AbCellera, a biotech perhaps best known for its work on Eli Lilly’s COVID-19 antibodies, has signed up a string of drug developers as partners in recent years on the strength of its discovery platform.